From: A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain
Description | Number of studies (study included) | Participants | RR (95% CI) | Remark | |
---|---|---|---|---|---|
With outcomes/total (buprenorphine group) | With outcomes/total (comparator) | ||||
TD route | |||||
Global impression of change | 96/120 | 72/121 | 1.35 (1.14-2.59); I2:42% | NNT: 4.9 (3.1-10.9) | |
Responders 35.5 μg/h | 27/76 | 17/75 | 1.58 (0.94-2.66); I2:39% | ||
Responders 52.5 μg/h | 37/75 | 17/75 | 1.83 (1.12-2.99); I2: 64% | NNT: 5.3 (3.06-24.09) | |
Responders 70 μg/h | 34/87 | 17/75 | 1.87 (1.17-3); I2: 0% | NNT: 5.03 (2.98-18.6) | |
Rescue SL buprenorphine | 79/247 | 23/84 | 1.25 (0.71-2.18); I2: 40% | ||
Requirement of prophylactic antiemetics | 24/129 | 53/110 | 0.63 (0.43-0.9); I2: 4% | NNT: 3.8 (2.4-8.4) | |
Requirement of laxatives | 45/151 | 70/160 | 1.03 (0.8-1.32); I2: 69% | ||
Nausea | 11/87 | 28/84 | 0.38 (0.2-0.71); I2: 0% | NNT: 9.3 (5.6-28.5) | |
Constipation | 32/77 | 33/71 | 0.89 (0.55-1.17); I2: 0% | TD fentanyl | |
Constipation | 30/87 | 36/84 | 0.89 (0.55-1.17); I2: 81% | Morphine | |
CNS- related AEs | 12/116 | 9/73 | 0.74 (0.33-1.66); I2: 0% | ||
Skin related AEs | 38/209 | 9/85 | 1.42 (0.73-2.76); I2: 16% | ||
SAEs Deaths | 3/155 | 1/75 | 1.48 (0.23-9.66); I2: 0% | ||
IM route | |||||
Any pain improvement (with 0.3 mg dose) | 22/42 | 6/34 | 3.03 (1.4-6.54); I2: 0% | ||
Any pain improvement (with 0.2 mg dose) | 23/35 | 6/34 | 3.7 (1.72-7.93); I2: 0% |